in patients with moderate to severe plaque psoriasis and scalp psoriasis. This trial highlighted the significant potential of guselkumab in treating psoriasis, which may boost the market. Additionally ...

Against the background described above, "betting big" on a topical treatment for plaque psoriasis make a lot of sense, ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Some people come home from a beach vacation and notice their skin looks clear and glowy. It's not their imagination. Unlike ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The likely GOP sweep of the House, Senate and White House has dampened expectations for health care policy riding in a lame-duck package.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other inflammatory skin diseases.